221 related articles for article (PubMed ID: 36937443)
41. Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
Wan Y; Luo D
J Gastrointest Oncol; 2023 Feb; 14(1):450-457. PubMed ID: 36915460
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study.
Jiang FE; Zhang HJ; Yu CY; Liu AN
Neoplasma; 2021 Jul; 68(4):861-866. PubMed ID: 33998237
[TBL] [Abstract][Full Text] [Related]
43. Regorafenib with or without a programmed cell death protein 1 antibody as third-line treatment for microsatellite stable metastatic colorectal cancer.
He WZ; Wang L; Yin CX; Yi JH; Jin YN; Jiang C; Guo GF; Xia LP
Cancer Med; 2023 Mar; 12(6):6488-6498. PubMed ID: 36373163
[TBL] [Abstract][Full Text] [Related]
44. Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study.
Dai X; Ding W; He Y; Huang S; Liu Y; Wu T
Front Oncol; 2023; 13():1227644. PubMed ID: 37681031
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of gemcitabine plus raltitrexed or S-1 versus standard third-line therapies in metastatic colorectal cancer: a retrospective cohort study.
Tao J; Zhang Y; Wang Y; Huang S; Gao W; Dai L; Feng Z; Jiao C; Zhang Y
J Gastrointest Oncol; 2024 Apr; 15(2):630-640. PubMed ID: 38756629
[TBL] [Abstract][Full Text] [Related]
46. Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer.
Gao Z; Cao C; Bao Y; Fan Y; Chen G; Fu P
Technol Cancer Res Treat; 2020; 19():1533033820943241. PubMed ID: 32914703
[TBL] [Abstract][Full Text] [Related]
47. Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
Signorelli C; Calegari MA; Basso M; Anghelone A; Lucchetti J; Minelli A; Angotti L; Zurlo IV; Schirripa M; Chilelli MG; Morelli C; Dell'Aquila E; Cosimati A; Gemma D; Ribelli M; Emiliani A; Corsi DC; Arrivi G; Mazzuca F; Zoratto F; Morandi MG; Santamaria F; Saltarelli R; Ruggeri EM
Curr Oncol; 2023 Jun; 30(6):5456-5469. PubMed ID: 37366896
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study.
Tan S; Zhang S; Zhou N; Cai X; Yi C; Gou H
Cancer Med; 2023 Dec; 12(24):22038-22046. PubMed ID: 38063405
[TBL] [Abstract][Full Text] [Related]
51. Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study.
Wang H; Liu W; Zhao Y; Hu H; Zhang B; Yang S
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e291-e299. PubMed ID: 36572661
[TBL] [Abstract][Full Text] [Related]
52. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio's prediction on effectiveness.
Xu YJ; Zhang P; Hu JL; Liang H; Zhu YY; Cui Y; Niu P; Xu M; Liu MY
World J Gastrointest Oncol; 2022 Apr; 14(4):920-934. PubMed ID: 35582108
[TBL] [Abstract][Full Text] [Related]
53. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
Zhang Y; Zou JY; Wang Z; Wang Y
Cancer Manag Res; 2019; 11():7787-7803. PubMed ID: 31496821
[TBL] [Abstract][Full Text] [Related]
54. A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.
Jin Y; Li J; Shen L; Xu J; Zhang Y; Zhang J; Pan H; Qu X; Chen Y; Zhang Q; Li J; Sun M; Qin S
Front Oncol; 2022; 12():1044328. PubMed ID: 36505849
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer.
Chen B; Zhao H; Huang J; Lv H; Xu W; Nie C; Wang J; Zhao J; He Y; Wang S; Chen X
BMC Geriatr; 2022 Dec; 22(1):987. PubMed ID: 36539696
[TBL] [Abstract][Full Text] [Related]
56. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of regorafenib as second-line treatment for patients with hepatocellular carcinoma and macrovascular invasion and(or) extrahepatic metastasis.
Zhao Y; Liu W; Zheng L; Goyal S; Awosika J; Wang H; Yang S
J Gastrointest Oncol; 2023 Dec; 14(6):2536-2548. PubMed ID: 38196538
[TBL] [Abstract][Full Text] [Related]
58. Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study.
Zhou H; Wang Y; Lin Y; Cai W; Li X; He X
Front Oncol; 2021; 11():774445. PubMed ID: 34900725
[TBL] [Abstract][Full Text] [Related]
59. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
BMC Cancer; 2024 Jan; 24(1):16. PubMed ID: 38166764
[TBL] [Abstract][Full Text] [Related]
60. Effect of cetuximab combined with chemotherapy in treating metastatic colorectal cancer and its prognostic analysis.
Wu J; Wang Z; Jin C; Ren H; Hu Y; Yang B; Hu Y
J BUON; 2021; 26(1):101-108. PubMed ID: 33721439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]